12:00 AM
Apr 14, 2016
 |  BC Innovations  |  Product R&D

AACR by the numbers

An AACR abstract preview by indications, targets and institutions

See Figure: Top indications

See Table: Novel cancer targets at AACR 2016

See Figure: Top institutions and companies

See Figure: Top targets


Novel cancer targets at AACR 2016
Breast cancer amplified sequence 1 (BCAS1)Non-small cell lung cancer (NSCLC)In vitro studies suggest knocking down BCAS1, a gene overexpressed in tumor tissues, could increase sensitivity of NSCLC cell lines to radiation.Dana-Farber Cancer Institute1650
Chromodomain helicase DNA binding protein 4 (CHD4)SarcomaProteomic and genetic screens , and mouse studies suggest silencing or depleting CHD4 could help treat paired box 3 (PAX3)-forkhead box O1 (FOXO1) fusion-positive rhabdomyosarcoma.University Children's Hospital Zurich; National Cancer Institute4457
Collagen triple helix repeat containing 1 (CTHRC1)NSCLCMouse studies suggest suppressing the transforming growth factor β (TGFβ) target gene CTHRC1 could help treat or prevent bone metastasis of...

Read the full 744 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$100 USD
More Info >